Search Results - "BUCKINGHAM, ROBIN E."

Refine Results
  1. 1

    Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury by Khandoudi, Nassirah, Delerive, Philippe, Berrebi-Bertrand, Isabelle, Buckingham, Robin E., Staels, Bart, Bril, Antoine

    Published in Diabetes (New York, N.Y.) (01-05-2002)
    “…Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ, Inhibits the Jun NH 2 -Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From…”
    Get full text
    Journal Article
  2. 2

    Thiazolidinedione Treatment Normalizes Insulin Resistance and Ischemic Injury in the Zucker Fatty Rat Heart by SIDELL, Robert J, COLE, Mark A, DRAPER, Nicholas J, DESROIS, Martine, BUCKINGHAM, Robin E, CLARKE, Kieran

    Published in Diabetes (New York, N.Y.) (01-04-2002)
    “…Thiazolidinedione Treatment Normalizes Insulin Resistance and Ischemic Injury in the Zucker Fatty Rat Heart Robert J. Sidell 1 , Mark A. Cole 1 , Nicholas J…”
    Get full text
    Journal Article
  3. 3

    Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat by Haynes, Andrea C, Jackson, Brian, Overend, Phil, Buckingham, Robin E, Wilson, Shelagh, Tadayyon, Mohammad, Arch, Jonathan R.S

    Published in Peptides (New York, N.Y. : 1980) (01-09-1999)
    “…Two novel hypothalamic neuropeptides, orexin-A and -B, are suggested to regulate feeding. A single intracerebroventricular injection of orexin-A (23.4 nmol),…”
    Get full text
    Journal Article
  4. 4

    Thiazolidinediones and their fluid-related adverse effects : Facts, fiction and putative management strategies by KARALLIEDDE, Janaka, BUCKINGHAM, Robin E

    Published in Drug safety (2007)
    “…Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the treatment of type 2 diabetes mellitus. These drugs have a multitude of…”
    Get full text
    Journal Article
  5. 5

    Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes by SCHEUERMANN-FREESTONE, Michaela, MADSEN, Per L, MANNERS, David, BLAMIRE, Andrew M, BUCKINGHAM, Robin E, STYLES, Peter, RADDA, George K, NEUBAUER, Stefan, CLARKE, Kieran

    Published in Circulation (New York, N.Y.) (24-06-2003)
    “…It is well known that patients with type 2 diabetes have increased risk of cardiovascular disease, but it is not known whether they have underlying…”
    Get full text
    Journal Article
  6. 6
  7. 7

    β-cell mass dynamics in Zucker diabetic fatty rats rosiglitazone prevents the rise in net cell death by FINEGOOD, Diane T, DAWN MCARTHUR, M, KOJWANG, David, THOMAS, Marion J, TOPP, Brian G, LEONARD, Thomas, BUCKINGHAM, Robin E

    Published in Diabetes (New York, N.Y.) (01-05-2001)
    “…The evolution of diabetes in the male leptin receptor-deficient (fa/fa) Zucker diabetic fatty (ZDF) rat is associated with disruption of normal islet…”
    Get full text
    Journal Article
  8. 8
  9. 9

    In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone by YUE, Tian-Li, JUN CHEN, HART, Timothy K, BUCKINGHAM, Robin E, OHLSTEIN, Eliot H, WEIKE BAO, NARAYANAN, Padma K, BRIL, Antoine, WEN JIANG, LYSKO, Paul G, GU, Juan-Li, BOYCE, Rogely, ZIMMERMAN, Dawn M

    Published in Circulation (New York, N.Y.) (20-11-2001)
    “…Diabetes is associated with increased risk of mortality as a consequence of acute myocardial infarction. This study determined whether rosiglitazone (ROSI)…”
    Get full text
    Journal Article
  10. 10

    The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats by WALKER, A. B, CHATTINGTON, P. D, BUCKINGHAM, R. E, WILLIAMS, G

    Published in Diabetes (New York, N.Y.) (01-07-1999)
    “…The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. A B Walker…”
    Get full text
    Journal Article
  11. 11

    Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord by Cutler, David J, Morris, Richard, Sheridhar, Vimal, Wattam, Trevor A.K, Holmes, Stephen, Patel, Sara, Arch, Jonathan R.S, Wilson, Shelagh, Buckingham, Robin E, Evans, Martyn L, Leslie, Ron A, Williams, Gareth

    Published in Peptides (New York, N.Y. : 1980) (01-12-1999)
    “…The orexins are recently identified appetite-stimulating hypothalamic peptides. We used immunohistochemistry to map orexin-A and orexin-B immunoreactivity in…”
    Get full text
    Journal Article
  12. 12

    Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro by WALKER, A. B, NADERALI, E. K, CHATTINGTON, P. D, BUCKINGHAM, R. E, WILLIAMS, G

    Published in Diabetes (New York, N.Y.) (01-05-1998)
    “…Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. A B Walker , E K…”
    Get full text
    Journal Article
  13. 13

    Central Exendin-4 Infusion Reduces Body Weight without Altering Plasma Leptin in ( ) Zucker Rats by Al‐Barazanji, Kamal A., Arch, Jonathan R. S., Buckingham, Robin E., Tadayyon, Mohammad

    Published in Obesity (Silver Spring, Md.) (01-07-2000)
    “…Objective: To investigate whether chronic administration of the long‐acting glucagon‐like peptide‐1 receptor agonist exendin‐4 can elicit sustained reductions…”
    Get full text
    Journal Article
  14. 14

    Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor? by Haynes, Andrea C, Arch, Jonathan R.S, Wilson, Shelagh, Steven Mc Clue, Buckingham, Robin E

    Published in Regulatory peptides (25-09-1998)
    “…Food intake was measured in freely fed rats following intracerebroventricular administration of neuropeptide Y (NPY) and several of its analogues and…”
    Get full text
    Journal Article
  15. 15

    The haemodynamic profile of cromakalim in the cat by Clapham, J C, Buckingham, R E

    Published in Journal of cardiovascular pharmacology (01-11-1988)
    “…The haemodynamic profile of the novel antihypertensive agent, cromakalim (BRL 34915), has been studied in conscious and anaesthetised cats. Given orally (0.03…”
    Get more information
    Journal Article
  16. 16

    β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats by Finegood, Diane T., McArthur, M. Dawn, Kojwang, David, Thomas, Marion J., Topp, Brian G., Leonard, Thomas, Buckingham, Robin E.

    Published in Diabetes (New York, N.Y.) (01-05-2001)
    “…β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats Rosiglitazone Prevents the Rise in Net Cell Death Diane T. Finegood 1 , M. Dawn McArthur 1 , David Kojwang 1…”
    Get full text
    Journal Article
  17. 17

    Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat by Buckingham, Robin E., Hamilton, Thomas C., Howlett, David R., Mootoo, Sheila, Wilson, Campbell

    Published in British journal of pharmacology (01-05-1989)
    “…1 In rat isolated thoracic aortic rings pre‐contracted with noradrenaline (10−6 m), cromakalim (3 × 10−7‐3 × 10−5 m) produced concentration‐related relaxation…”
    Get full text
    Journal Article
  18. 18

    Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone by Cai, Xue J., Lister, Carolyn A., Buckingham, Robin E., Pickavance, Lucy, Wilding, John, Arch, Jonathan R.S., Wilson, Shelagh, Williams, Gareth

    Published in Brain research. Molecular brain research. (14-04-2000)
    “…Orexins (hypocretins) are lateral hypothalamic neuropeptides implicated in regulating feeding and the sleep–wake cycle. To study their possible relevance to…”
    Get full text
    Journal Article
  19. 19

    Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans by Ashwood, Valerie A, Buckingham, Robin E, Cassidy, Frederick, Evans, John M, Faruk, Erol A, Hamilton, Thomas C, Nash, David J, Stemp, Geoffrey, Willcocks, Kenneth

    Published in Journal of medicinal chemistry (01-11-1986)
    “…The synthesis and antihypertensive activity of a series of novel 4-(cyclic amido)-2H-1-benzopyran-3-ols, administered orally to conscious spontaneously…”
    Get full text
    Journal Article
  20. 20

    Differences between the Vasorelaxant Activity of Adenosine-receptor Agonists on Guinea-pig Isolated Aorta Precontracted with Noradrenaline or Phenylephrine by FORD, WILLIAM R., MADDOCK, HELEN L., BUCKINGHAM, ROBIN E., BROADLEY, KENNETH J.

    Published in Journal of pharmacy and pharmacology (01-10-1999)
    “…The relaxant effect of adenosine and 5′‐(N‐ethylcarboxamido)adenosine (NECA) against α‐adrenoceptor‐mediated contractile tone in guinea‐pig isolated aortic…”
    Get full text
    Journal Article